Advertisement

Brain Metastases

  • Balamurugan A. Vellayappan
  • Arjun Sahgal
  • Kristin J. Redmond
  • Lia M. Halasz
  • Eric L. Chang
  • Simon S. LoEmail author
Chapter
  • 38 Downloads
Part of the Medical Radiology book series (MEDRAD)

Abstract

Brain metastases (BM) cause significant morbidity and mortality, with profound personal and societal impact. Historically, surgery and whole-brain radiotherapy (WBRT) were the mainstays of management. WBRT alone has been shown to have limited role for durable local control, and there are concerns regarding its impact on quality of life (QoL) and neurocognitive function. Advances in systemic therapeutics have afforded improved control of extracranial disease and paved the way for improved survival outcomes. In parallel, the overarching goals of BM management are to provide durable intracranial control and good QoL, with minimal long-term toxicities, and, if possible, to prolong survival. However, there remain significant controversies within the oncology community about how these goals should be achieved. Herein, we will review various management strategies, including the role of stereotactic radiosurgery (SRS) and methods to mitigate long-term toxicity of WBRT.

References

  1. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363(9422):1665–1672CrossRefPubMedPubMedCentralGoogle Scholar
  2. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K et al (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295(21):2483–2491CrossRefPubMedPubMedCentralGoogle Scholar
  3. Aoyama H, Tago M, Kato N, Toyoda T, Kenjyo M, Hirota S et al (2007) Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 68(5):1388–1395CrossRefPubMedPubMedCentralGoogle Scholar
  4. Aoyama H, Tago M, Shirato H (2015) Japanese Radiation Oncology Study Group I. Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: secondary analysis of the JROSG 99-1 randomized clinical trial. JAMA Oncol 1(4):457–464CrossRefPubMedPubMedCentralGoogle Scholar
  5. Armstrong TS, Wefel JS, Wang M, Won M, Bottomley A, Mendoza TR, Coens C, Werner-Wasik M, Brachman D, Choucair AK, Gilbert MR (2011) Clinical utility of neurocognitive function (NCF), quality of life (QOL), and symptom assessment as prognostic factors for survival and measures of treatment effects on RTOG 0525. Journal of Clinical Oncology 2011 29:15_suppl, 2016–2016Google Scholar
  6. Ayala-Peacock DN, Peiffer AM, Lucas JT, Isom S, Kuremsky JG, Urbanic JJ et al (2014) A nomogram for predicting distant brain failure in patients treated with gamma knife stereotactic radiosurgery without whole brain radiotherapy. Neuro Oncol 16(9):1283–1288CrossRefPubMedPubMedCentralGoogle Scholar
  7. Bachelot T, Romieu G, Campone M, Dieras V, Cropet C, Dalenc F et al (2013) Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 14(1):64–71CrossRefPubMedPubMedCentralGoogle Scholar
  8. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22(14):2865–2872CrossRefPubMedPubMedCentralGoogle Scholar
  9. Barnholtz-Sloan JS, Yu C, Sloan AE, Vengoechea J, Wang M, Dignam JJ et al (2012) A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro Oncol 14(7):910–918CrossRefPubMedPubMedCentralGoogle Scholar
  10. Baschnagel AM, Meyer KD, Chen PY, Krauss DJ, Olson RE, Pieper DR et al (2013) Tumor volume as a predictor of survival and local control in patients with brain metastases treated with Gamma Knife surgery. J Neurosurg 119(5):1139–1144CrossRefPubMedPubMedCentralGoogle Scholar
  11. Bauman G, Yartsev S, Fisher B, Kron T, Laperriere N, Heydarian M et al (2007) Simultaneous infield boost with helical tomotherapy for patients with 1 to 3 brain metastases. Am J Clin Oncol 30(1):38–44CrossRefPubMedPubMedCentralGoogle Scholar
  12. Bhatnagar AK, Flickinger JC, Kondziolka D, Lunsford LD (2006) Stereotactic radiosurgery for four or more intracranial metastases. Int J Radiat Oncol Biol Phys 64(3):898–903CrossRefPubMedPubMedCentralGoogle Scholar
  13. Bindal AK, Bindal RK, Hess KR, Shiu A, Hassenbusch SJ, Shi WM et al (1996) Surgery versus radiosurgery in the treatment of brain metastasis. J Neurosurg 84(5):748–754CrossRefPubMedPubMedCentralGoogle Scholar
  14. Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW et al (1980) The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 6(1):1–9CrossRefPubMedPubMedCentralGoogle Scholar
  15. Borgelt B, Gelber R, Larson M, Hendrickson F, Griffin T, Roth R (1981) Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 7(12):1633–1638CrossRefPubMedPubMedCentralGoogle Scholar
  16. Brennan C, Yang TJ, Hilden P, Zhang Z, Chan K, Yamada Y et al (2014) A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases. Int J Radiat Oncol Biol Phys 88(1):130–136CrossRefPubMedPubMedCentralGoogle Scholar
  17. Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C et al (2013) Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol 15(10):1429–1437CrossRefPubMedPubMedCentralGoogle Scholar
  18. Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK et al (2016a) Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA 316(4):401–409CrossRefPubMedPubMedCentralGoogle Scholar
  19. Brown PD, Ballman KV, Cerhan J, Anderson SK et al (2016b) N107C/CEC.3: a phase III trial of post-operative Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for resected metastatic brain disease. Int J Radiat Oncol Biol Phys 96:937CrossRefGoogle Scholar
  20. Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR et al (2011) The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res 71(7):2488–2496CrossRefPubMedPubMedCentralGoogle Scholar
  21. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG et al (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112(3):533–543CrossRefPubMedPubMedCentralGoogle Scholar
  22. Chang EL, Selek U, Hassenbusch SJ 3rd, Maor MH, Allen PK, Mahajan A et al (2005) Outcome variation among “radioresistant” brain metastases treated with stereotactic radiosurgery. Neurosurgery 56(5):936–945. ; discussion–45PubMedPubMedCentralGoogle Scholar
  23. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG et al (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10(11):1037–1044CrossRefPubMedPubMedCentralGoogle Scholar
  24. Chao JH, Phillips R, Nickson JJ (1954) Roentgen-ray therapy of cerebral metastases. Cancer 7(4):682–689CrossRefPubMedPubMedCentralGoogle Scholar
  25. Chapman A, MacKenzie A, Parker I (2015) Silver oncologic tsunami: quality issues in the senior adult oncology population. J Oncol Pract 11(3):190–192CrossRefPubMedPubMedCentralGoogle Scholar
  26. Chatani M, Teshima T, Inoue T, Inoue T, Harada K, Hori S (1986) Radiation therapy of brain metastases from pulmonary carcinoma--intensive course versus high-dose course. Nihon Igaku Hoshasen Gakkai Zasshi 46(8):1041–1047PubMedPubMedCentralGoogle Scholar
  27. Chevreau C, Ravaud A, Escudier B, Amela E, Delva R, Rolland F et al (2014) A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases. Clin Genitourin Cancer 12(1):50–54CrossRefPubMedPubMedCentralGoogle Scholar
  28. Choi CY, Chang SD, Gibbs IC, Adler JR, Harsh GR, Lieberson RE et al (2012) Stereotactic radiosurgery of the postoperative resection cavity for brain metastases: prospective evaluation of target margin on tumor control. Int J Radiat Oncol Biol Phys 84(2):336–342CrossRefPubMedPubMedCentralGoogle Scholar
  29. Chougule PBB-WM, Saris S, Zheng Z, Ponte B, Noren G, Alderson L, Friehs G, Wazer D, Epstein M (2000) Randomized treatment of brain metastases with gamma knife radiosurgery, whole brain radiotherapy or both [abstract]. Int J Radiat Oncol Biol Phys 48(3):114CrossRefGoogle Scholar
  30. Christakis NA, Lamont EB (2000) Extent and determinants of error in physicians’ prognoses in terminally ill patients: prospective cohort study. West J Med 172(5):310–313CrossRefPubMedPubMedCentralGoogle Scholar
  31. DeAngelis LM, Delattre JY, Posner JB (1989) Radiation-induced dementia in patients cured of brain metastases. Neurology 39(6):789–796CrossRefPubMedPubMedCentralGoogle Scholar
  32. Defrancesco M, Marksteiner J, Deisenhammer E, Kemmler G, Djurdjevic T, Schocke M (2013) Impact of white matter lesions and cognitive deficits on conversion from mild cognitive impairment to Alzheimer’s disease. J Alzheimers Dis 34(3):665–672CrossRefPubMedPubMedCentralGoogle Scholar
  33. DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR (1979) The natural history of breast cancer patients with brain metastases. Cancer 44(5):1913–1918CrossRefPubMedPubMedCentralGoogle Scholar
  34. Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L et al (2014) Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 50(3):611–621CrossRefPubMedPubMedCentralGoogle Scholar
  35. Flickinger JC, Kondziolka D, Lunsford LD, Coffey RJ, Goodman ML, Shaw EG et al (1994) A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. Int J Radiat Oncol Biol Phys 28(4):797–802CrossRefPubMedPubMedCentralGoogle Scholar
  36. Fox BD, Cheung VJ, Patel AJ, Suki D, Rao G (2011) Epidemiology of metastatic brain tumors. Neurosurg Clin N Am 22(1):1–6. vCrossRefPubMedPubMedCentralGoogle Scholar
  37. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A et al (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300(5622):1155–1159CrossRefPubMedPubMedCentralGoogle Scholar
  38. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37(4):745–751CrossRefPubMedPubMedCentralGoogle Scholar
  39. Gaspar LE, Scott C, Murray K, Curran W (2000) Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 47(4):1001–1006CrossRefPubMedPubMedCentralGoogle Scholar
  40. Giovagnoli AR, Silvani A, Colombo E, Boiardi A (2005) Facets and determinants of quality of life in patients with recurrent high grade glioma. J Neurol Neurosurg Psychiatry 76(4):562–568CrossRefPubMedPubMedCentralGoogle Scholar
  41. Glantz MJ, LaFollette S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR et al (1999a) Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 17(10):3110–3116CrossRefPubMedPubMedCentralGoogle Scholar
  42. Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ et al (1999b) A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 5(11):3394–3402PubMedPubMedCentralGoogle Scholar
  43. Gondi V, Tome WA, Marsh J, Struck A, Ghia A, Turian JV et al (2010a) Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: safety profile for RTOG 0933. Radiother Oncol 95(3):327–331CrossRefPubMedPubMedCentralGoogle Scholar
  44. Gondi V, Tolakanahalli R, Mehta MP, Tewatia D, Rowley H, Kuo JS et al (2010b) Hippocampal-sparing whole-brain radiotherapy: a “how-to” technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 78(4):1244–1252CrossRefPubMedPubMedCentralGoogle Scholar
  45. Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A et al (2014) Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol 32(34):3810–3816CrossRefPubMedPubMedCentralGoogle Scholar
  46. Gore EM, Bae K, Wong SJ, Sun A, Bonner JA, Schild SE et al (2011) Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol 29(3):272–278CrossRefPubMedPubMedCentralGoogle Scholar
  47. Gregor A, Cull A, Stephens RJ, Kirkpatrick JA, Yarnold JR, Girling DJ et al (1997) Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 33(11):1752–1758CrossRefPubMedPubMedCentralGoogle Scholar
  48. Grossman SA, Krabak MJ (1999) Leptomeningeal carcinomatosis. Cancer Treat Rev 25(2):103–119CrossRefPubMedPubMedCentralGoogle Scholar
  49. Guerrieri M, Wong K, Ryan G, Millward M, Quong G, Ball DL (2004) A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer 46(1):107–111CrossRefPubMedPubMedCentralGoogle Scholar
  50. Gutierrez AN, Westerly DC, Tome WA, Jaradat HA, Mackie TR, Bentzen SM et al (2007) Whole brain radiotherapy with hippocampal avoidance and simultaneously integrated brain metastases boost: a planning study. Int J Radiat Oncol Biol Phys 69(2):589–597CrossRefPubMedPubMedCentralGoogle Scholar
  51. Haie-Meder C, Pellae-Cosset B, Laplanche A, Lagrange JL, Tuchais C, Nogues C et al (1993) Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases. Radiother Oncol 26(2):111–116CrossRefPubMedPubMedCentralGoogle Scholar
  52. Halasz LM, Weeks JC, Neville BA, Taback N, Punglia RS (2013) Use of stereotactic radiosurgery for brain metastases from non-small cell lung cancer in the United States. Int J Radiat Oncol Biol Phys 85(2):e109–e116CrossRefPubMedPubMedCentralGoogle Scholar
  53. Halasz LM, Uno H, Hughes M, D’Amico T, Dexter EU, Edge SB et al (2016) Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer. Cancer 122(13):2091–2100CrossRefPubMedPubMedCentralGoogle Scholar
  54. Hall MD, McGee JL, McGee MC, Hall KA, Neils DM, Klopfenstein JD et al (2014) Cost-effectiveness of stereotactic radiosurgery with and without whole-brain radiotherapy for the treatment of newly diagnosed brain metastases. J Neurosurg 121(Suppl):84–90CrossRefPubMedPubMedCentralGoogle Scholar
  55. Harwood AR, Simson WJ (1977) Radiation therapy of cerebral metastases: a randomized prospective clinical trial. Int J Radiat Oncol Biol Phys 2(11–12):1091–1094CrossRefPubMedPubMedCentralGoogle Scholar
  56. Hasegawa T, Kondziolka D, Flickinger JC, Germanwala A, Lunsford LD (2003) Brain metastases treated with radiosurgery alone: an alternative to whole brain radiotherapy? Neurosurgery 52(6):1318–1326. ; discussion 26CrossRefPubMedPubMedCentralGoogle Scholar
  57. Hermann B, Hultenschmidt B, Sautter-Bihl ML (2001) Radiotherapy of the neuroaxis for palliative treatment of leptomeningeal carcinomatosis. Strahlenther Onkol 177(4):195–199CrossRefPubMedPubMedCentralGoogle Scholar
  58. Horton J, Baxter DH, Olson KB (1971) The management of metastases to the brain by irradiation and corticosteroids. Am J Roentgenol Radium Ther Nucl Med 111(2):334–336CrossRefPubMedPubMedCentralGoogle Scholar
  59. Hsu F, Carolan H, Nichol A, Cao F, Nuraney N, Lee R et al (2010) Whole brain radiotherapy with hippocampal avoidance and simultaneous integrated boost for 1-3 brain metastases: a feasibility study using volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys 76(5):1480–1485CrossRefPubMedPubMedCentralGoogle Scholar
  60. Hulst HE, Steenwijk MD, Versteeg A, Pouwels PJ, Vrenken H, Uitdehaag BM et al (2013) Cognitive impairment in MS: impact of white matter integrity, gray matter volume, and lesions. Neurology 80(11):1025–1032CrossRefPubMedPubMedCentralGoogle Scholar
  61. Hutchinson TA, Boyd NF, Feinstein AR, Gonda A, Hollomby D, Rowat B (1979) Scientific problems in clinical scales, as demonstrated in the Karnofsky index of performance status. J Chronic Dis 32(9–10):661–666CrossRefPubMedPubMedCentralGoogle Scholar
  62. Johnson DR, Sawyer AM, Meyers CA, O’Neill BP, Wefel JS (2012) Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma. Neuro Oncol 14(6):808–816CrossRefPubMedPubMedCentralGoogle Scholar
  63. Karlsson B, Hanssens P, Wolff R, Soderman M, Lindquist C, Beute G (2009) Thirty years’ experience with Gamma Knife surgery for metastases to the brain. J Neurosurg 111(3):449–457CrossRefPubMedPubMedCentralGoogle Scholar
  64. Kim SY, Kim JS, Park HS, Cho MJ, Kim JO, Kim JW et al (2005) Screening of brain metastasis with limited magnetic resonance imaging (MRI): clinical implications of using limited brain MRI during initial staging for non-small cell lung cancer patients. J Korean Med Sci 20(1):121–126CrossRefPubMedPubMedCentralGoogle Scholar
  65. Kim KH, Lee J, Lee JI, Nam do H, Kong DS, Ahn YC et al (2010) Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases? Lung Cancer 68(2):258–263CrossRefPubMedPubMedCentralGoogle Scholar
  66. Knisely JP, Yamamoto M, Gross CP, Castrucci WA, Jokura H, Chiang VL (2010) Radiosurgery alone for 5 or more brain metastases: expert opinion survey. J Neurosurg 113(Suppl):84–89CrossRefPubMedPubMedCentralGoogle Scholar
  67. Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL (2012) Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 117(2):227–233CrossRefPubMedPubMedCentralGoogle Scholar
  68. Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG et al (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 29(2):134–141CrossRefPubMedPubMedCentralGoogle Scholar
  69. Kocher M, Wittig A, Piroth MD, Treuer H, Seegenschmiedt H, Ruge M et al (2014) Stereotactic radiosurgery for treatment of brain metastases. A report of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol 190(6):521–532CrossRefPubMedPubMedCentralGoogle Scholar
  70. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC (1999) Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 45(2):427–434CrossRefPubMedPubMedCentralGoogle Scholar
  71. Kondziolka D, Parry PV, Lunsford LD, Kano H, Flickinger JC, Rakfal S et al (2014) The accuracy of predicting survival in individual patients with cancer. J Neurosurg 120(1):24–30CrossRefPubMedPubMedCentralGoogle Scholar
  72. Krepler P, Kummer M, Pawlowsky J, Jentzsch K (1975) Prevention of meningeal leukaemia and relapses by cranial irradiation and intrathecal MTX in acute lymphatic leukaemia. Acta Neuropathol Suppl Suppl 6:241–245. PMID: 1057842Google Scholar
  73. Krown SE, Niedzwiecki D, Hwu WJ, Hodgson L, Houghton AN, Haluska FG et al (2006) Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer 107(8):1883–1890CrossRefPubMedPubMedCentralGoogle Scholar
  74. Kurtz JM, Gelber R, Brady LW, Carella RJ, Cooper JS (1981) The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 7(7):891–895CrossRefPubMedPubMedCentralGoogle Scholar
  75. Lal LS, Byfield SD, Chang EL, Franzini L, Miller LA, Arbuckle R et al (2012) Cost-effectiveness analysis of a randomized study comparing radiosurgery with radiosurgery and whole brain radiation therapy in patients with 1 to 3 brain metastases. Am J Clin Oncol 35(1):45–50CrossRefPubMedPubMedCentralGoogle Scholar
  76. Langley RE, Stephens RJ, Nankivell M, Pugh C, Moore B, Navani N et al (2013) Interim data from the Medical Research Council QUARTZ Trial: does whole brain radiotherapy affect the survival and quality of life of patients with brain metastases from non-small cell lung cancer? Clin Oncol (R Coll Radiol) 25(3):e23–e30CrossRefGoogle Scholar
  77. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y et al (2009) Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114(3):589–595CrossRefPubMedPubMedCentralGoogle Scholar
  78. Lee SM, Lewanski CR, Counsell N, Ottensmeier C, Bates A, Patel N et al (2014) Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases. J Natl Cancer Inst 106(7):dju151CrossRefPubMedPubMedCentralGoogle Scholar
  79. Leksell L (1951) The stereotaxic method and radiosurgery of the brain. Acta Chir Scand 102(4):316–319PubMedPubMedCentralGoogle Scholar
  80. Li J, Bentzen SM, Renschler M, Mehta MP (2007) Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol 25(10):1260–1266CrossRefPubMedPubMedCentralGoogle Scholar
  81. Li J, Bentzen SM, Li J, Renschler M, Mehta MP (2008) Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. Int J Radiat Oncol Biol Phys 71(1):64–70CrossRefPubMedPubMedCentralGoogle Scholar
  82. Likhacheva A, Pinnix CC, Parikh NR, Allen PK, McAleer MF, Chiu MS et al (2013) Predictors of survival in contemporary practice after initial radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 85(3):656–661CrossRefPubMedPubMedCentralGoogle Scholar
  83. Lim SH, Lee JY, Lee MY, Kim HS, Lee J, Sun JM et al (2015) A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer. Ann Oncol 26(4):762–768CrossRefPubMedPubMedCentralGoogle Scholar
  84. Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ et al (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15(4):1452–1459CrossRefPubMedPubMedCentralGoogle Scholar
  85. Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG et al (2015) Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 16(6):e270–e278CrossRefPubMedPubMedCentralGoogle Scholar
  86. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB et al (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13(11):1087–1095CrossRefPubMedPubMedCentralGoogle Scholar
  87. Manon R, O’Neill A, Knisely J, Werner-Wasik M, Lazarus HM, Wagner H et al (2005) Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397). J Clin Oncol 23(34):8870–8876CrossRefPubMedPubMedCentralGoogle Scholar
  88. Mehta M, Noyes W, Craig B, Lamond J, Auchter R, French M et al (1997) A cost-effectiveness and cost-utility analysis of radiosurgery vs. resection for single-brain metastases. Int J Radiat Oncol Biol Phys 39(2):445–454CrossRefPubMedPubMedCentralGoogle Scholar
  89. Meyers CA, Hess KR (2003) Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro Oncol 5(2):89–95CrossRefPubMedPubMedCentralGoogle Scholar
  90. Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T et al (2004) Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22(1):157–165CrossRefPubMedPubMedCentralGoogle Scholar
  91. Mintz AH, Kestle J, Rathbone MP, Gaspar L, Hugenholtz H, Fisher B et al (1996) A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 78(7):1470–1476CrossRefPubMedPubMedCentralGoogle Scholar
  92. Muacevic A, Wowra B, Siefert A, Tonn JC, Steiger HJ, Kreth FW (2008) Microsurgery plus whole brain irradiation versus Gamma Knife surgery alone for treatment of single metastases to the brain: a randomized controlled multicentre phase III trial. J Neurooncol 87(3):299–307CrossRefPubMedPubMedCentralGoogle Scholar
  93. Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, et al (2016) Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet 2016, 388:2004–2014Google Scholar
  94. Murray KJ, Scott C, Greenberg HM, Emami B, Seider M, Vora NL et al (1997) A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys 39(3):571–574CrossRefPubMedPubMedCentralGoogle Scholar
  95. Narayana A, Mathew M, Tam M, Kannan R, Madden KM, Golfinos JG et al (2013) Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 113(3):411–416CrossRefPubMedPubMedCentralGoogle Scholar
  96. Neuhaus T, Ko Y, Muller RP, Grabenbauer GG, Hedde JP, Schueller H et al (2009) A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Br J Cancer 100(2):291–297CrossRefPubMedPubMedCentralGoogle Scholar
  97. Nieder C, Berberich W, Schnabel K (1997) Tumor-related prognostic factors for remission of brain metastases after radiotherapy. Int J Radiat Oncol Biol Phys 39(1):25–30CrossRefPubMedPubMedCentralGoogle Scholar
  98. Nieder C, Nestle U, Walter K, Niewald M, Schnabel K (1998) Dose/effect relationships for brain metastases. J Cancer Res Clin Oncol 124(6):346–350CrossRefPubMedPubMedCentralGoogle Scholar
  99. Nieder C, Spanne O, Mehta MP, Grosu AL, Geinitz H (2011) Presentation, patterns of care, and survival in patients with brain metastases: what has changed in the last 20 years? Cancer 117(11):2505–2512CrossRefPubMedPubMedCentralGoogle Scholar
  100. Nieder C, Norum J, Dalhaug A, Aandahl G, Pawinski A (2013) Radiotherapy versus best supportive care in patients with brain metastases and adverse prognostic factors. Clin Exp Metastasis 30(6):723–729CrossRefPubMedPubMedCentralGoogle Scholar
  101. Noordijk EM, Vecht CJ, Haaxma-Reiche H, Padberg GW, Voormolen JH, Hoekstra FH et al (1994) The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 29(4):711–717CrossRefPubMedPubMedCentralGoogle Scholar
  102. Nussbaum ES, Djalilian HR, Cho KH, Hall WA (1996) Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 78(8):1781–1788CrossRefPubMedPubMedCentralGoogle Scholar
  103. Onodera S, Aoyama H, Tha KK, Hashimoto N, Toyomaki A, Terae S et al (2014) The value of 4-month neurocognitive function as an endpoint in brain metastases trials. J Neurooncol 120(2):311–319CrossRefPubMedPubMedCentralGoogle Scholar
  104. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322(8):494–500CrossRefPubMedPubMedCentralGoogle Scholar
  105. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ et al (1998) Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280(17):1485–1489CrossRefPubMedPubMedCentralGoogle Scholar
  106. Pirzkall A, Debus J, Lohr F, Fuss M, Rhein B, Engenhart-Cabillic R et al (1998) Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol 16(11):3563–3569CrossRefPubMedPubMedCentralGoogle Scholar
  107. Qian JM, Yu JB, Kluger HM, Chiang VL (2016) Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer 122(19):3051–3058CrossRefPubMedPubMedCentralGoogle Scholar
  108. Rades D, Kueter JD, Veninga T, Gliemroth J, Schild SE (2009) Whole brain radiotherapy plus stereotactic radiosurgery (WBRT + SRS) versus surgery plus whole brain radiotherapy (OP + WBRT) for 1-3 brain metastases: results of a matched pair analysis. Eur J Cancer 45(3):400–404CrossRefPubMedPubMedCentralGoogle Scholar
  109. Rao G, Ahmed S, Hess K, Mahajan A (2016) 215 postoperative stereotactic radiosurgery vs observation for completely resected brain metastases: results of a Prospective Randomized Study. Neurosurgery 63(Suppl 1):184CrossRefGoogle Scholar
  110. Rapp SR, Case LD, Peiffer A, Naughton MM, Chan MD, Stieber VW et al (2015) Donepezil for irradiated brain tumor survivors: a phase III randomized placebo-controlled clinical trial. J Clin Oncol 33(15):1653–1659CrossRefPubMedPubMedCentralGoogle Scholar
  111. Regine WF, Scott C, Murray K, Curran W (2001) Neurocognitive outcome in brain metastases patients treated with accelerated-fractionation vs. accelerated-hyperfractionated radiotherapy: an analysis from Radiation Therapy Oncology Group Study 91-04. Int J Radiat Oncol Biol Phys 51(3):711–717CrossRefPubMedPubMedCentralGoogle Scholar
  112. Regine WF, Huhn JL, Patchell RA, St Clair WH, Strottmann J, Meigooni A et al (2002) Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: results and implications. Int J Radiat Oncol Biol Phys 52(2):333–338CrossRefPubMedPubMedCentralGoogle Scholar
  113. Rodrigues G, Warner A, Zindler J, Slotman B, Lagerwaard F (2014) A clinical nomogram and recursive partitioning analysis to determine the risk of regional failure after radiosurgery alone for brain metastases. Radiother Oncol 111(1):52–58CrossRefPubMedPubMedCentralGoogle Scholar
  114. Roos DE, Smith JG, Stephens SW (2011) Radiosurgery versus surgery, both with adjuvant whole brain radiotherapy, for solitary brain metastases: a randomised controlled trial. Clin Oncol (R Coll Radiol) 23(9):646–651CrossRefGoogle Scholar
  115. Sahgal A, Aoyama H, Kocher M, Neupane B, Collette S, Tago M et al (2015) Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 91(4):710–717CrossRefPubMedPubMedCentralGoogle Scholar
  116. Sanghavi SN, Miranpuri SS, Chappell R, Buatti JM, Sneed PK, Suh JH et al (2001) Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol Biol Phys 51(2):426–434CrossRefPubMedPubMedCentralGoogle Scholar
  117. Savitz ST, Chen RC, Sher DJ (2015) Cost-effectiveness analysis of neurocognitive-sparing treatments for brain metastases. Cancer 121(23):4231–4239CrossRefPubMedPubMedCentralGoogle Scholar
  118. Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J et al (2000) Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 47(2):291–298CrossRefPubMedPubMedCentralGoogle Scholar
  119. Smedby KE, Brandt L, Backlund ML, Blomqvist P (2009) Brain metastases admissions in Sweden between 1987 and 2006. Br J Cancer 101(11):1919–1924CrossRefPubMedPubMedCentralGoogle Scholar
  120. Sneed PK, Lamborn KR, Forstner JM, McDermott MW, Chang S, Park E et al (1999) Radiosurgery for brain metastases: is whole brain radiotherapy necessary? Int J Radiat Oncol Biol Phys 43(3):549–558CrossRefPubMedPubMedCentralGoogle Scholar
  121. Soffietti R, Kocher M, Abacioglu UM, Villa S, Fauchon F, Baumert BG et al (2013) A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol 31(1):65–72CrossRefPubMedPubMedCentralGoogle Scholar
  122. Soltys SG, Adler JR, Lipani JD, Jackson PS, Choi CY, Puataweepong P et al (2008) Stereotactic radiosurgery of the postoperative resection cavity for brain metastases. Int J Radiat Oncol Biol Phys 70(1):187–193CrossRefPubMedPubMedCentralGoogle Scholar
  123. Soon YY, Tham IW, Lim KH, Koh WY, Lu JJ (2014) Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases. Cochrane Database Syst Rev 3:CD009454Google Scholar
  124. Soon YY, Leong CN, Koh WY, Tham IW (2015) EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis. Radiother Oncol 114(2):167–172CrossRefPubMedPubMedCentralGoogle Scholar
  125. Sorensen JB, Klee M, Palshof T, Hansen HH (1993) Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 67(4):773–775CrossRefPubMedPubMedCentralGoogle Scholar
  126. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W (2008) A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70(2):510–514CrossRefPubMedPubMedCentralGoogle Scholar
  127. Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D et al (2010) Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 77(3):655–661CrossRefPubMedPubMedCentralGoogle Scholar
  128. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X et al (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30(4):419–425CrossRefPubMedPubMedCentralGoogle Scholar
  129. Sperduto PW, Wang M, Robins HI, Schell MC, Werner-Wasik M, Komaki R et al (2013) A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 85(5):1312–1318CrossRefPubMedPubMedCentralGoogle Scholar
  130. Sperduto PW, Shanley R, Luo X, Andrews D, Werner-Wasik M, Valicenti R et al (2014) Secondary analysis of RTOG 9508, a phase 3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain metastases; poststratified by the graded prognostic assessment (GPA). Int J Radiat Oncol Biol Phys 90(3):526–531CrossRefPubMedPubMedCentralGoogle Scholar
  131. Stokes TB, Niranjan A, Kano H, Choi PA, Kondziolka D, Dade Lunsford L et al (2015) White matter changes in breast cancer brain metastases patients who undergo radiosurgery alone compared to whole brain radiation therapy plus radiosurgery. J Neurooncol 121(3):583–590CrossRefPubMedPubMedCentralGoogle Scholar
  132. Sturm V, Kober B, Hover KH, Schlegel W, Boesecke R, Pastyr O et al (1987) Stereotactic percutaneous single dose irradiation of brain metastases with a linear accelerator. Int J Radiat Oncol Biol Phys 13(2):279–282CrossRefPubMedPubMedCentralGoogle Scholar
  133. Sun A, Bae K, Gore EM, Movsas B, Wong SJ, Meyers CA et al (2011) Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol 29(3):279–286CrossRefPubMedPubMedCentralGoogle Scholar
  134. Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE et al (2012a) Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2(3):210–225CrossRefPubMedPubMedCentralGoogle Scholar
  135. Tsao M, Xu W, Sahgal A (2012b) A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases. Cancer 118(9):2486–2493CrossRefPubMedPubMedCentralGoogle Scholar
  136. Tsao MN, Khuntia D, Mehta MP (2012c) Brain metastases: what’s new with an old problem? Curr Opin Support Palliat Care 6(1):85–90CrossRefPubMedPubMedCentralGoogle Scholar
  137. Vecht CJ, Hovestadt A, Verbiest HB, van Vliet JJ, van Putten WL (1994) Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 44(4):675–680CrossRefPubMedPubMedCentralGoogle Scholar
  138. Vuong DA, Rades D, Le AN, Busse R (2012) The cost-effectiveness of stereotactic radiosurgery versus surgical resection in the treatment of brain metastasis in Vietnam from the perspective of patients and families. World Neurosurg 77(2):321–328CrossRefPubMedPubMedCentralGoogle Scholar
  139. Vuong DA, Rades D, van Eck AT, Horstmann GA, Busse R (2013) Comparing the cost-effectiveness of two brain metastasis treatment modalities from a payer’s perspective: stereotactic radiosurgery versus surgical resection. Clin Neurol Neurosurg 115(3):276–284CrossRefPubMedPubMedCentralGoogle Scholar
  140. Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK et al (2013) Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 31(7):895–902CrossRefPubMedPubMedCentralGoogle Scholar
  141. Wolfson AH, Snodgrass SM, Schwade JG, Markoe AM, Landy H, Feun LG et al (1994) The role of steroids in the management of metastatic carcinoma to the brain. A pilot prospective trial. Am J Clin Oncol 17(3):234–238CrossRefPubMedPubMedCentralGoogle Scholar
  142. Yamamoto M, Kawabe T, Sato Y, Higuchi Y, Nariai T, Watanabe S et al (2014) Stereotactic radiosurgery for patients with multiple brain metastases: a case-matched study comparing treatment results for patients with 2-9 versus 10 or more tumors. J Neurosurg 121(Suppl):16–25CrossRefPubMedPubMedCentralGoogle Scholar
  143. Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS, Chrysikos D, de Azambuja E et al (2013) Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. Breast Cancer Res Treat 139(1):13–22CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Balamurugan A. Vellayappan
    • 1
  • Arjun Sahgal
    • 2
  • Kristin J. Redmond
    • 3
  • Lia M. Halasz
    • 4
  • Eric L. Chang
    • 5
  • Simon S. Lo
    • 6
    Email author
  1. 1.Department of Radiation OncologyNational University Cancer InstituteSingaporeSingapore
  2. 2.Department of Radiation OncologySunnybrook Health Sciences Center, University of TorontoTorontoCanada
  3. 3.Department of Radiation Oncology and Molecular Radiation SciencesJohns Hopkins UniversityBaltimoreUSA
  4. 4.Department of Radiation OncologyUniversity of Washington School of MedicineSeattleUSA
  5. 5.Department of Radiation OncologyUniversity of Southern CaliforniaLos AngelesUSA
  6. 6.Department of Radiation OncologyUniversity of Washington School of MedicineSeattleUSA

Personalised recommendations